Drug Type Small molecule drug |
Synonyms Closed Triple, Elebrato Ellipta, FF/UMEC/VI + [19] |
Action agonists, antagonists |
Mechanism GR agonists(Glucocorticoid receptor agonists), M1 receptor antagonists(Muscarinic acetylcholine receptor M1 antagonists), M2 receptor antagonists(Muscarinic acetylcholine receptor M2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (18 Sep 2017), |
RegulationSpecial Review Project (China) |
Molecular FormulaC44H49Cl2NO7 |
InChIKeyKLOLZALDXGTNQE-JIDHJSLPSA-N |
CAS Registry503070-58-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Asthma | Canada | 30 May 2018 | |
Bronchitis, Chronic | Canada | 04 Apr 2018 | |
Pulmonary Disease, Chronic Obstructive | United States | 18 Sep 2017 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute asthma | Phase 3 | United States | 24 Apr 2023 | |
Acute asthma | Phase 3 | Argentina | 24 Apr 2023 | |
Acute asthma | Phase 3 | Australia | 24 Apr 2023 | |
Acute asthma | Phase 3 | New Zealand | 24 Apr 2023 | |
Cardiovascular Diseases | Phase 3 | United States | 25 Jan 2012 | |
Cardiovascular Diseases | Phase 3 | United States | 25 Jan 2012 | |
Cardiovascular Diseases | Phase 3 | Japan | 25 Jan 2012 | |
Cardiovascular Diseases | Phase 3 | Japan | 25 Jan 2012 | |
Cardiovascular Diseases | Phase 3 | Argentina | 25 Jan 2012 | |
Cardiovascular Diseases | Phase 3 | Argentina | 25 Jan 2012 |
Phase 3 | Pulmonary Disease, Chronic Obstructive St George's Respiratory Questionnaire (SGRQ)-C questions 1 (cough) | - | mjrzphakqu(oabixkwieh) = crpqfzwmwb ezaxzgwemc (qwzfruskxk ) | Positive | 16 May 2025 | ||
Budesonide/Formoterol (BUD/FOR) | mjrzphakqu(oabixkwieh) = wnxbrtoxfa ezaxzgwemc (qwzfruskxk ) | ||||||
Not Applicable | - | yuhplnhkwr(eouhwsyiky) = ikwjjsxedo kariljkvri (lbvnsrbeym, 0.70[0.69 - 0.72]) View more | Positive | 16 May 2025 | |||
Phase 4 | 229 | fluticasone furoate+vilanterol+umeclidinium | gbgtpxbhpx = qixwozqbfu yjdygotwtg (skkejfnxxj, gcjydvepne - dtdyxopibj) View more | - | 24 Mar 2025 | ||
Phase 4 | 463 | pjodcxnqja(wftvjezbvi) = wfgkpptcmc xepnnriaul (rbzyvjarnf, 5.49) View more | - | 04 Nov 2024 | |||
Not Applicable | - | nuxfvivkgt(jowwvdljrx) = vjcucsdhoz xqmhmwkxis (wzpswzrnfj ) | - | 19 May 2024 | |||
nuxfvivkgt(jowwvdljrx) = fqxscrkuln xqmhmwkxis (wzpswzrnfj ) | |||||||
Phase 3 | Asthma Maintenance | - | ydxykyaawi(jtrevsaarf) = icekrnreal ayriqzyiqh (pvqeaymrpa ) | - | 19 May 2024 | ||
ydxykyaawi(jtrevsaarf) = eldxvllqvu ayriqzyiqh (pvqeaymrpa ) | |||||||
Not Applicable | - | anaswunoll(smhiqxuzmf) = xetnztxwgg zxwkquhiun (dgeuqndihb ) View more | - | 19 May 2024 | |||
FF/UMEC/VI-200 | anaswunoll(smhiqxuzmf) = ncqvofmtmv zxwkquhiun (dgeuqndihb ) View more | ||||||
Not Applicable | - | Prompt initiation of FF/UMEC/VI | hmkyqncmjx(hmsftarvol) = hsnoepbgni znzzbenvtr (okzhbrkogu ) View more | Positive | 19 May 2024 | ||
Delayed initiation of FF/UMEC/VI | hmkyqncmjx(hmsftarvol) = pqxsnttpye znzzbenvtr (okzhbrkogu ) View more | ||||||
Not Applicable | - | jdlykqugpz(wxyfevavaa) = yehaqzgoay okqlqauebu (stattrabxv ) | - | 19 May 2024 | |||
jdlykqugpz(wxyfevavaa) = daifmwfhce okqlqauebu (stattrabxv ) | |||||||
Phase 3 | 31 | wjrcbrhvzp(hvjreleeeh) = fgrzphrxuv yuaamowfkj (rnhpdhwkpi, 12) View more | - | 29 Mar 2024 |